Balanced news tone
News Sentiment
CU6 sentiment intelligence
Clarity Pharmaceuticals Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
92/100 classification confidence.
directly relevant articles
high-authority source matches
+9.0% over one week, +12.1% over four weeks, trend inactive, and below fair value.
Clarity Pharmaceuticals (ASX:CU6) Shares Advance While Investors Focus on Pipeline Progress
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Clarity Pharmaceuticals (ASX:CU6) Shares Advance While Investors Focus on Pipeline Progress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 09:53
- Source
- Kalkine
Is Clarity Pharmaceuticals (ASX:CU6) Redefining Cancer Treatment Through Its Copper Theranostics Platform?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 07:00
- Source
- Kalkine Media
Is Clarity Pharmaceuticals’ (ASX:CU6) Copper Theranostics Pipeline Redefining Its Long-Term Oncology Strategy?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 19:41
- Source
- simplywall.st
Clarity Pharmaceuticals (ASX:CU6) Rallies Nearly 15%: Is This ASX Healthcare Stock Worth Watching?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 07:00
- Source
- Kalkine
ASX: CU6 Climbs as Precision Oncology Developer Draws Market Attention
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 07:00
- Source
- Kalkine
Clarity Pharmaceuticals (ASX:CU6) Gains as Radiopharma Stocks Stay Hot
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Kalkine
Clarity Pharmaceuticals (ASX:CU6) Advances Prostate Cancer Research, Shares Gain Attention
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Jun 2026 07:00
- Source
- Kalkine Media
Clarity Pharmaceuticals Shares Close At 52-Week Low: The Latest
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- thebull.com.au
Clarity Pharmaceuticals (ASX:CU6): Biotech Stock Falls as Investors Watch Trial Progress
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Kalkine
Clarity Pharmaceuticals (ASX:CU6) Plunges as Clinical-Stage Biotech Sell-Off Continues
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 07:00
- Source
- Kalkine
Clarity Pharmaceuticals (CU6 ASX: CU6) Rises 9% as Traders Rotate Into Biotech Stocks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 07:00
- Source
- Kalkine
Clarity Pharmaceuticals Limited (ASX:CU6): Biotech Darling Faces a Defining Technical Crossroads
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 07:00
- Source
- Kalkine
Clarity Pharmaceuticals (ASX: CU6) Advances Amid Oncology Pipeline Progress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 07:00
- Source
- Kalkine
Trade Alert: CEO, MD & Executive Director Of Clarity Pharmaceuticals Michelle Parker Has Sold Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Apr 2026 07:00
- Source
- simplywall.st
Why Clarity Pharmaceuticals shares just fell 5% on today’s announcement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Apr 2026 07:00
- Source
- The Motley Fool Australia
Inside Clarity Pharmaceuticals' (ASX:CU6) Manufacturing Deal:
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Apr 2026 07:00
- Source
- Kalkine
Why Is Clarity Pharmaceuticals (ASX:CU6) Stock Surging Today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Mar 2026 07:00
- Source
- Kalkine
Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- The Motley Fool Australia
Clarity Pharmaceuticals Valuation After AMPLIFY Trial Recruitment Surges Past Initial Target
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 12 Mar 2026 07:00
- Source
- simplywall.st
Clarity Pharmaceuticals H1 2026 Loss Worsening Challenges Bullish Profitability Narrative
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Feb 2026 08:00
- Source
- simplywall.st
Why Clarity Pharmaceuticals, EOS, Nuix, and Reece shares are racing higher today
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Feb 2026 08:00
- Source
- The Motley Fool Australia
Clarity Pharmaceuticals Ltd's (ASX:CU6) market cap dropped AU$145m last week; individual investors who hold 48% were hit as were institutions
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jan 2026 08:00
- Source
- simplywall.st
Why 4DMedical, Amaero, Clarity Pharmaceuticals, and Treasury Wine shares are falling today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jan 2026 08:00
- Source
- The Motley Fool Australia
Clarity Pharmaceuticals Ltd (ASX:CU6): Is Breakeven Near?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Dec 2025 08:00
- Source
- simplywall.st
Insights: Clarity Pharmaceuticals Ltd (ASX:CU6)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Oct 2025 15:46
- Source
- smallcaps.com.au
Clarity Pharmaceuticals Ltd (ASX:CU6) Is Expected To Breakeven In The Near Future
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Oct 2025 07:00
- Source
- Market source